Venous thromboembolism - Expanding therapeutic options
Venous thromboembolism (VTE) is caused by the formation of blood clots within a vein resulting in vein occlusion and risk of blood clots travelling to the pulmonary arteries. VTE manifestations are deep vein thrombosis (DVT) and pulmonary embolism (PE). Until recently, standard therapy for VTE inclu...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2013-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/1210 |
| _version_ | 1797841615152218112 |
|---|---|
| author | I. A. Filippova |
| author_facet | I. A. Filippova |
| author_sort | I. A. Filippova |
| collection | DOAJ |
| description | Venous thromboembolism (VTE) is caused by the formation of blood clots within a vein resulting in vein occlusion and risk of blood clots travelling to the pulmonary arteries. VTE manifestations are deep vein thrombosis (DVT) and pulmonary embolism (PE). Until recently, standard therapy for VTE included daily injections of heparin with a subsequent transition to oral intake of vitamin K antagonist warfarin. Registration of the oral anticoagulant Xarelto in the RF as a treatment for deep vein thrombosis, pulmonary embolism and prevention of recurrent DVT and PE opens new opportunities for both professionals and patients. |
| first_indexed | 2024-04-09T16:34:09Z |
| format | Article |
| id | doaj.art-260d7fc291ba47f194053314b48ed927 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:34:09Z |
| publishDate | 2013-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-260d7fc291ba47f194053314b48ed9272023-04-23T06:56:58ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902013-12-01069910110.21518/2079-701X-2013-6-99-1011210Venous thromboembolism - Expanding therapeutic optionsI. A. Filippova0Мedical CouncilVenous thromboembolism (VTE) is caused by the formation of blood clots within a vein resulting in vein occlusion and risk of blood clots travelling to the pulmonary arteries. VTE manifestations are deep vein thrombosis (DVT) and pulmonary embolism (PE). Until recently, standard therapy for VTE included daily injections of heparin with a subsequent transition to oral intake of vitamin K antagonist warfarin. Registration of the oral anticoagulant Xarelto in the RF as a treatment for deep vein thrombosis, pulmonary embolism and prevention of recurrent DVT and PE opens new opportunities for both professionals and patients.https://www.med-sovet.pro/jour/article/view/1210венозная тромбоэмболияновые оральные антикоагулянтыривароксабанvenous thromboembolismnew oral anticoagulantsrivaroxaban |
| spellingShingle | I. A. Filippova Venous thromboembolism - Expanding therapeutic options Медицинский совет венозная тромбоэмболия новые оральные антикоагулянты ривароксабан venous thromboembolism new oral anticoagulants rivaroxaban |
| title | Venous thromboembolism - Expanding therapeutic options |
| title_full | Venous thromboembolism - Expanding therapeutic options |
| title_fullStr | Venous thromboembolism - Expanding therapeutic options |
| title_full_unstemmed | Venous thromboembolism - Expanding therapeutic options |
| title_short | Venous thromboembolism - Expanding therapeutic options |
| title_sort | venous thromboembolism expanding therapeutic options |
| topic | венозная тромбоэмболия новые оральные антикоагулянты ривароксабан venous thromboembolism new oral anticoagulants rivaroxaban |
| url | https://www.med-sovet.pro/jour/article/view/1210 |
| work_keys_str_mv | AT iafilippova venousthromboembolismexpandingtherapeuticoptions |